Talecris Commences Initial Public Offering of Common Stock

Talecris Commences Initial Public Offering of Common Stock

Featured Broker sponsored link
 RESEARCH TRIANGLE PARK, N.C.--(Business Wire)--
Talecris Biotherapeutics Holdings Corp. ("Talecris") today announced the launch
of its initial public offering of 44,736,842 shares of its common stock, par
value $0.01 per share. Talecris is a global biotherapeutic and biotechnology
company that discovers, develops and produces critical care treatments for
people with life-threatening disorders in a variety of therapeutic areas
including immunology, neurology, pulmonology and hemostasis.

Of the shares being offered, 28,947,368 are being offered by Talecris and
15,789,474 are being offered by the selling stockholder, Talecris Holdings, LLC.
Talecris Holdings, LLC is owned by Cerberus-Plasma Holdings, LLC, the managing
member of which is Cerberus Partners, L.P., and limited partnerships affiliated
with Ampersand Ventures. The initial public offering price is expected to be
between $18.00 and $20.00 per share. Talecris has applied to have the shares of
common stock approved for quotation on The Nasdaq Global Market under the ticker
symbol "TLCR." The underwriters have the option to purchase from the selling
stockholder up to an additional 6,710,526 shares of common stock, on the same
terms and conditions.

Talecris intends to use the net proceeds of the offering to repay amounts owed
under its First Lien Term Loan Credit Agreement and Second Lien Term Loan Credit
Agreement. Talecris will not receive any of the proceeds from the offering of
the common stock by the selling stockholder.

Morgan Stanley, Goldman, Sachs & Co., Citigroup Global Markets Inc. and J.P.
Morgan Securities Inc. are acting as joint book-running managers for the
proposed offering. Wells Fargo Securities, LLC, Barclays Capital Inc. and UBS
Investment Bank are acting as co-managers.

Copies of the preliminary prospectus relating to the offering may be obtained by
contacting: Morgan Stanley & Co. Incorporated, Attention: Prospectus Department,
180 Varick Street, New York, New York 10014, telephone 1-866-718-1649 or by
emailing [email protected]; Goldman, Sachs & Co., Prospectus
Department, 85 Broad Street, New York, New York 10004, telephone 1-866-471-2526,
facsimile 1-212-902-9316 or by emailing [email protected]; Citigroup
Global Markets Inc. at Brooklyn Army Terminal, 140 58th Street, 8th Floor,
Brooklyn, New York 11220, telephone 1-800-831-9146; or J.P. Morgan Securities
Inc., 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245, Attention:
Prospectus Department, telephone 718-242-8002.

A registration statement relating to these securities has been filed with the
Securities and Exchange Commission but has not yet become effective. These
securities may not be sold nor may offers to buy be accepted prior to the time
the registration statement becomes effective. This press release shall not
constitute an offer to sell or a solicitation of an offer to buy any securities,
nor shall there be any such offer or solicitation or any sale of securities in
any state or jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of any
such state or jurisdiction.

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.